Drug Profile
Busulfan liposomal - Calliditas Therapeutics
Alternative Names: Busulipo; MZH-2Latest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator Karolinska Institute
- Developer Calliditas Therapeutics
- Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
- Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bone marrow transplant rejection
Most Recent Events
- 24 Sep 2020 No development reported - Phase-II for Bone marrow transplant rejection (Prevention) in Sweden (IV) (Calliditas Therapeutics website, September 2020)
- 04 Jan 2012 Pharmalink completes phase II trials in Cancer as a myeloablative agent in Sweden
- 14 Apr 2008 Phase-II clinical trials in Bone marrow transplant rejection (Prevention) in Sweden (IV)